June 2025. Volume 21. Number 2

Prolonged prednisone treatment does not reduce relapses in children with steroid-sensitive nephrotic syndrome

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Hahn D, Samuel SM, Willis NS, Craig JC, Hodson EM. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2024; 22;(8):CD001533.

Reviewers: Pérez González E1, Balado Insunza MN2.
1Servicio de Pediatría. Hospital Universitario Virgen Macarena. Sevilla. España.
2Servicio de Pediatría. Hospital Álvaro Cunqueiro. Vigo. Pontevedra. España.
Correspondence: Elena Pérez González. Email: pg.elena@gmail.com
Reception date: 26/05/2025
Acceptance date: 09/06/2025
Publication date: 25/06/2025

Abstract

Authors' conclusions: studies showed that there is no benefit in prolonging prednisone treatment beyond two to three months in the first episode of steroid-sensitive nephrotic syndrome and intercurrent disease, with no increased risk of relapse. Small studies in children with relapsing disease have not identified differences in efficacy using lower induction doses or shorter durations of prednisone, although further studies are required to confirm these findings.

Reviewers' commentary: this is a systematic review that suggests the usefulness of shorter steroid regimens in both first and subsequent relapses in SSNS. The usefulness of lower doses of corticosteroids in relapse remains to be confirmed, as well as the decrease in direct and indirect side effects derived from the shorter treatment time.

How to cite this article

Pérez González E, Balado Insunza N. Prolongar el tratamiento con prednisona no disminuye las recaídas en el síndrome nefrótico corticosensible. Evid Pediatr. 2025;21:23.

AVC | Critically appraised articles

Hahn D, Samuel SM, Willis NS, Craig JC, Hodson EM. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2024; 22;(8):CD001533.

Reviewers: Pérez González E1, Balado Insunza MN2.
1Servicio de Pediatría. Hospital Universitario Virgen Macarena. Sevilla. España.
2Servicio de Pediatría. Hospital Álvaro Cunqueiro. Vigo. Pontevedra. España.
Correspondence: Elena Pérez González. Email: pg.elena@gmail.com
Reception date: 26/05/2025
Acceptance date: 09/06/2025
Publication date: 25/06/2025

How to cite this article

Pérez González E, Balado Insunza N. Prolongar el tratamiento con prednisona no disminuye las recaídas en el síndrome nefrótico corticosensible. Evid Pediatr. 2025;21:23.


Related Articles

ED | Duración del tratamiento con corticoides en el síndrome nefrótico infantil: de la tradición a la evidencia

Antón Gamero M. Duración del tratamiento con corticoides en el síndrome nefrótico infantil: de la tradición a la evidencia. Evid Pediatr. 2025;21:13.
25/06/2025

Linked Comment